PDP-716 FDA Approval Status
Last updated by Judith Stewart, BPharm on Jan 5, 2023.
FDA Approved: No
Brand name: PDP-716
Generic name: brimonidine tartrate
Company: Visiox Pharma, LLC
Treatment for: Glaucoma, Open Angle, Glaucoma/Intraocular Hypertension
PDP-716 (brimonidine tartrate 0.35%) is a once-daily ophthalmic formulation of the approved alpha adrenergic agonist brimonidine in development for the treatment of ocular hypertension and open angle glaucoma.
- PDP-716 is formulated using patented TearAct™ fine resin technology, which provides slow, consistent, and sustained drug delivery to improve drug bioavailability and drug exposure, and potentially allowing for once-daily administration of brimonidine tartrate.
- Brimonidine tartrate is a well-established treatment for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is currently available in ophthalmic solution formulations under the brand names Alphagan P (0.1% and 0.15%) and Qoliana (0.15%), which are administered three times daily.
Development timeline for PDP-716
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
